Effectiveness of doxazosin on erectile dysfunction in patients with lower urinary tract symptoms

McVary KT (2005) Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 47:838–845

Costabile RA, Steers WD (2006) How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 3:676–681

Carson CC (2006) Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 97:39–43

Shiri R, Häkkinen JT, Hakama M et al (2005) Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. J Urol 174:205–209

Lowe FC (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJU Int 95:12–18

Krieger JN, Nyberg L Jr, Nickel JC (1999) NIH consensus definition and classification of prostatitis. JAMA 282:236–237

Barry MJ, Fowler FJ Jr, O’Leary MP et al (1992) The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 148:1549–1557

Rosen RC, Cappelleri JC, Smith MD et al (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319–326

Marszalek M, Wehrberger C, Hochreiter W et al (2007) Symptoms suggestive of chronic pelvic pain syndrome in an urban population: prevalence and associations with lower urinary tract symptoms and erectile function. J Urol 177:1815–1819

Rosen RC, Giuliano F, Carson CC (2005) Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 47:824–837

McVary K (2006) Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 97:23–28

Braun MH, Sommer F, Haupt G et al (2003) Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical “Aging Male” symptoms? Results of the “Cologne Male Survey”. Eur Urol 44:588–594

Rosen R, Altwein J, Boyle P et al (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44:637–649

Rosen RC, Wei JT, Althof SE et al (2009) Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH registry. Urology 73:562–566

Kirby RS, Andersen M, Gratzke P et al (2001) A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 87:192–200

De Rose AF, Carmignani G, Corbu C et al (2002) Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 68:95–98

Fawzy A, Braun K, Lewis GP et al (1995) Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 154:105–109

Andersen M, Dahlstrand C, Høye K (2000) Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 38:400–409

Kirby RS, Roehrborn C, Boyle P et al (2003) Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective European doxazosin and combination therapy (PREDICT) trial. Urology 61:119–126

Robert G, Descazeaud A, Nicolaïew N et al (2009) Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 69:1774–1780